According to the Zhongguancun announcement, Shandong Huasu Pharmaceutical Co., Ltd., a subsidiary of the company, has received the “Drug Registration Certificate” approved and issued by the State Drug Administration. The bisoprolol amlodipine tablets developed by it have passed the drug registration review and approval. The registration classification is classified as 4 types of chemicals, and the drug is valid for 18 months. As of August 31, 2026, the project had invested 9.3737 million yuan in R&D expenses. This drug is a treatment for high blood pressure. Approval will enrich the company's product line, and there is uncertainty about its future production and sales.

According to the Zhongguancun announcement, Shandong Huasu Pharmaceutical Co., Ltd., a subsidiary of the company, has received the “Drug Registration Certificate” approved and issued by the State Drug Administration. The bisoprolol amlodipine tablets developed by it have passed the drug registration review and approval. The registration classification is classified as 4 types of chemicals, and the drug is valid for 18 months. As of August 31, 2026, the project had invested 9.3737 million yuan in R&D expenses. This drug is a treatment for high blood pressure. Approval will enrich the company's product line, and there is uncertainty about its future production and sales.